<DOC>
	<DOCNO>NCT00368017</DOCNO>
	<brief_summary>The substantially increase cardiovascular morbidity mortality rate chronic kidney disease ( CKD ) patient sufficiently explain traditional coronary risk factor . It apparent inflammation vessel wall play essential role pathophysiology atherosclerosis , strong association elevate inflammatory biomarkers cardiovascular death support mechanism . Approximately 50 % mortality population patient attributable cardiovascular disease . Insulin resistance also common problem uremic patient . It show insulin resistance may contribute atherosclerotic cardiovascular disease . An intriguing observation CKD patient advance uremia metabolic profile patient characterized persistent low-grade inflammation , state insulin resistance , significantly increase prevalence atherosclerosis . It possible metabolic derangement incite factor development progression uremic atherosclerosis . Peroxisome proliferator-activated receptor gamma ( PPAR-gamma ) ligand-activated nuclear transcription factor find cell immune system vasculature , exert overall protective effect development atherosclerosis , part modulation inflammation . The agonist PPAR-gamma improve insulin resistance , also profound beneficial effect inflammation , oxidative stress , endothelium , lipid metabolism . In proposal , investigator hypothesize short-term administration PPAR-gamma agonist ( pioglitazone ) improve inflammatory state , insulin resistance , endothelial dysfunction chronic kidney disease patient advance uremia .</brief_summary>
	<brief_title>Metabolic Effects Thiazolidinediones Chronic Kidney Disease</brief_title>
	<detailed_description />
	<mesh_term>Kidney Diseases</mesh_term>
	<mesh_term>Renal Insufficiency , Chronic</mesh_term>
	<mesh_term>Pioglitazone</mesh_term>
	<mesh_term>2,4-thiazolidinedione</mesh_term>
	<criteria>1 . Patients Stage 3 4 chronic kidney disease measure Modification Diet Renal Disease Study ( MDRD ) estimate 15 ml/min 59 ml/min . 2 . Age 18 75 year old . 3 . Patients without hospitalization cardiac infection relate morbidity previous four week ( due potential confounding effect baseline study variable ) . 4 . Patients able provide consent participate study . 1 . Patients prior document diagnosis diabetes mellitus . 2 . Patients fast blood glucose &gt; 110mg/dL . 3 . Prisoners , patient significant mental illness , pregnant woman , vulnerable population . 4 . Patients active hepatic disease and/or ALT &gt; 2.5 time upper limit normal . 5 . Patients history congestive heart failure NYHA Class IIIIV symptoms time . 6 . Patients live donor renal transplantation already schedule process evaluate , patient unlikely complete study protocol transplantation . 7 . Patients severe comorbid condition ( eg , symptomatic hepatic cirrhosis , metastatic cancer , HIV infection AIDS ) . 8 . Patient active inflammatory process ( eg. , SLE , rheumatoid arthritis , gout ) currently receive immune modulating medication . 9 . Patients corticosteroid therapy . 10 . Patients consent participate study .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>75 Years</maximum_age>
	<verification_date>November 2010</verification_date>
</DOC>